663,602 Shares in Health Catalyst, Inc. (NASDAQ:HCAT) Acquired by Portolan Capital Management LLC

Portolan Capital Management LLC bought a new position in Health Catalyst, Inc. (NASDAQ:HCAT) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 663,602 shares of the company’s stock, valued at approximately $5,402,000. Portolan Capital Management LLC owned 1.09% of Health Catalyst at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. First Light Asset Management LLC lifted its holdings in shares of Health Catalyst by 438.5% in the second quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company’s stock valued at $25,279,000 after buying an additional 3,221,408 shares during the period. Impax Asset Management Group plc raised its position in Health Catalyst by 16.4% in the third quarter. Impax Asset Management Group plc now owns 2,554,475 shares of the company’s stock worth $20,793,000 after acquiring an additional 360,201 shares in the last quarter. Millennium Management LLC lifted its holdings in Health Catalyst by 96.3% in the 2nd quarter. Millennium Management LLC now owns 2,413,280 shares of the company’s stock valued at $15,421,000 after acquiring an additional 1,184,131 shares during the last quarter. Primecap Management Co. CA boosted its position in shares of Health Catalyst by 1.1% during the 3rd quarter. Primecap Management Co. CA now owns 2,404,462 shares of the company’s stock valued at $19,572,000 after purchasing an additional 25,000 shares in the last quarter. Finally, Daventry Group LP grew its stake in shares of Health Catalyst by 3.9% in the 2nd quarter. Daventry Group LP now owns 2,247,053 shares of the company’s stock worth $14,359,000 after purchasing an additional 84,178 shares during the last quarter. 85.00% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

HCAT has been the subject of several recent research reports. Piper Sandler reissued an “overweight” rating and set a $12.00 target price (up from $11.00) on shares of Health Catalyst in a research note on Tuesday, November 26th. Royal Bank of Canada increased their price objective on Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a research report on Thursday, November 7th. Evercore ISI lifted their target price on Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a report on Tuesday, October 8th. Citigroup upped their target price on Health Catalyst from $9.00 to $10.50 and gave the company a “buy” rating in a report on Wednesday, November 13th. Finally, Stephens lifted their price target on Health Catalyst from $7.00 to $9.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 14th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, Health Catalyst has a consensus rating of “Moderate Buy” and an average price target of $11.79.

Health Catalyst Stock Down 12.0 %

Health Catalyst stock opened at $7.94 on Wednesday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. Health Catalyst, Inc. has a fifty-two week low of $5.42 and a fifty-two week high of $11.41. The firm has a fifty day moving average price of $8.14 and a two-hundred day moving average price of $7.35. The firm has a market cap of $483.15 million, a price-to-earnings ratio of -5.88 and a beta of 1.31.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The business had revenue of $76.40 million during the quarter, compared to the consensus estimate of $76.27 million. During the same quarter in the previous year, the firm posted ($0.22) earnings per share. The company’s revenue for the quarter was up 3.5% on a year-over-year basis. As a group, analysts forecast that Health Catalyst, Inc. will post -0.33 earnings per share for the current year.

Insider Transactions at Health Catalyst

In other news, insider Kevin Lee Freeman sold 7,500 shares of Health Catalyst stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $8.94, for a total transaction of $67,050.00. Following the sale, the insider now owns 236,950 shares of the company’s stock, valued at approximately $2,118,333. This trade represents a 3.07 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Daniel Lesueur sold 5,209 shares of the company’s stock in a transaction on Thursday, October 3rd. The shares were sold at an average price of $7.68, for a total value of $40,005.12. Following the completion of the transaction, the chief operating officer now owns 134,899 shares of the company’s stock, valued at $1,036,024.32. The trade was a 3.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 25,931 shares of company stock worth $208,777 over the last three months. 2.50% of the stock is currently owned by insiders.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.